NURIX THERAPEUTICS, INC. Earnings Per Share (Diluted)
NURIX THERAPEUTICS, INC. (NRIX) reported Earnings Per Share (Diluted) of -$0.81 per share for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-05-31 was -$0.81.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-02-28 was -$0.79.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-11-30 was -$0.82.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-08-31 was -$1.03.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for fiscal 2025 was -$3.05.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was -$2.88.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$2.65.
- NURIX THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$3.71.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$0.81 10-Q · filed 2026-07-09 | -$1.60 10-Q · filed 2026-07-09 | -$2.42 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$3.41 derived: net income ÷ weighted average shares · filed 2026-07-09 |
| 2026-02-28 | -$0.79 10-Q · filed 2026-04-08 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$2.61 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$3.17 derived: net income ÷ weighted average shares · filed 2026-07-09 |
| 2025-11-30 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.37 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$3.05 10-K · filed 2026-01-28 |
| 2025-08-31 | -$1.03 10-Q · filed 2025-10-09 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$2.22 10-Q · filed 2025-10-09 | -$2.97 derived: net income ÷ weighted average shares · filed 2026-07-09 |
| 2025-05-31 | -$0.52 10-Q · filed 2026-07-09 | -$1.19 10-Q · filed 2026-07-09 | -$1.93 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$2.60 derived: net income ÷ weighted average shares · filed 2026-07-09 |
| 2025-02-28 | -$0.67 10-Q · filed 2026-04-08 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$2.09 derived: net income ÷ weighted average shares · filed 2026-07-09 | -$2.81 derived: net income ÷ weighted average shares · filed 2026-07-09 |
| 2024-11-30 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.14 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.88 10-K · filed 2026-01-28 |
| 2024-08-31 | -$0.67 10-Q · filed 2025-10-09 | -$1.38 derived: net income ÷ weighted average shares · filed 2025-10-09 | -$2.13 10-Q · filed 2025-10-09 | -$2.89 derived: net income ÷ weighted average shares · filed 2026-01-28 |
| 2024-05-31 | -$0.71 10-Q · filed 2025-07-09 | -$1.47 10-Q · filed 2025-07-09 | -$2.23 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.92 derived: net income ÷ weighted average shares · filed 2026-01-28 |
| 2024-02-29 | -$0.76 10-Q · filed 2025-04-08 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.20 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.65 derived: net income ÷ weighted average shares · filed 2026-01-28 |
| 2023-11-30 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-01-28 | -$2.65 10-K · filed 2026-01-28 |
| 2023-08-31 | -$0.68 10-Q · filed 2024-10-11 | -$1.13 derived: net income ÷ weighted average shares · filed 2024-10-11 | -$1.88 10-Q · filed 2024-10-11 | -$2.75 derived: net income ÷ weighted average shares · filed 2025-01-28 |
| 2023-05-31 | -$0.45 10-Q · filed 2024-07-11 | -$1.20 10-Q · filed 2024-07-11 | -$2.07 derived: net income ÷ weighted average shares · filed 2025-01-28 | -$2.96 derived: net income ÷ weighted average shares · filed 2025-01-28 |
| 2023-02-28 | -$0.75 10-Q · filed 2024-04-10 | -$1.62 derived: net income ÷ weighted average shares · filed 2025-01-28 | -$2.52 derived: net income ÷ weighted average shares · filed 2025-01-28 | -$3.51 derived: net income ÷ weighted average shares · filed 2025-01-28 |
| 2022-11-30 | -$0.87 derived: net income ÷ weighted average shares · filed 2025-01-28 | -$1.76 derived: net income ÷ weighted average shares · filed 2025-01-28 | -$2.76 derived: net income ÷ weighted average shares · filed 2025-01-28 | -$3.71 10-K · filed 2025-01-28 |
| 2022-08-31 | -$0.90 10-Q · filed 2023-10-12 | -$1.90 derived: net income ÷ weighted average shares · filed 2023-10-12 | -$2.85 10-Q · filed 2023-10-12 | -$3.70 derived: net income ÷ weighted average shares · filed 2023-10-12 |
| 2022-05-31 | -$1.01 10-Q · filed 2023-07-13 | -$1.96 10-Q · filed 2023-07-13 | -$2.81 derived: net income ÷ weighted average shares · filed 2023-10-12 | -$3.46 derived: net income ÷ weighted average shares · filed 2023-10-12 |
| 2022-02-28 | -$0.95 10-Q · filed 2023-04-13 | -$1.80 derived: net income ÷ weighted average shares · filed 2023-10-12 | -$2.45 derived: net income ÷ weighted average shares · filed 2023-10-12 | -$3.05 derived: net income ÷ weighted average shares · filed 2023-10-12 |
| 2021-11-30 | -$0.85 derived: net income ÷ weighted average shares · filed 2023-02-09 | -$1.50 derived: net income ÷ weighted average shares · filed 2023-02-09 | -$2.10 derived: net income ÷ weighted average shares · filed 2023-02-09 | -$2.73 10-K · filed 2023-02-09 |
| 2021-08-31 | -$0.65 10-Q · filed 2022-10-06 | -$1.25 derived: net income ÷ weighted average shares · filed 2022-10-06 | -$1.88 10-Q · filed 2022-10-06 | |
| 2021-05-31 | -$0.60 10-Q · filed 2022-07-07 | -$1.23 10-Q · filed 2022-07-07 | ||
| 2020-08-31 | -$1.09 10-Q · filed 2021-10-14 | -$1.00 derived: net income ÷ weighted average shares · filed 2021-10-14 | -$2.90 10-Q · filed 2021-10-14 | |
| 2020-05-31 | $0.00 10-Q · filed 2021-07-13 | -$1.32 10-Q · filed 2021-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |